The collaboration has resulted in a clinical feasibility trial of GRIP Molecular Technologies’ patented electronic biosensor technology which is intended to give customers a lab-quality, multi-disease diagnostic test results in minutes
GRIP Molecular Technologies joins forces with Molecular Testing Labs on new at-home disease testing platform. (Credit: Louis Reed on Unsplash)
GRIP Molecular Technologies and US-based laboratory Molecular Testing Labs (MTL) have partnered to develop a new at-home disease testing platform.
Their collaboration has resulted in a clinical feasibility trial of GRIP Molecular Technologies’ patented electronic biosensor technology.
According to Molecular Testing Labs, the technology is intended to directly give customers lab-quality, multi-disease diagnostic test results in minutes.
Under this technology, GRIP Molecular Technologies’ disposable diagnostic cartridge uses self-collected samples to display the test results on a standard smartphone and further send them to the user’s clinician.
This allows for the virtual application of timely therapy, rapid disease diagnosis, and data-informed telehealth interaction, Molecular Testing Labs said.
GRIP Molecular Technologies founder and chief technology officer Bruce Batten said: “Using MTL’s highly characterised infected patient nasal swab samples, we have bolstered prior evidence of the GRIP technology’s extraordinary performance capabilities, with combined levels of diagnostic speed, convenience, and accuracy not possible with alternative technologies available for home use.
“Evidence shows the prompt application of appropriate therapy is important to maximise its beneficial impact — and typically this is within 48 hours of symptom onset when many home-based diagnostics provide concerningly low levels of accuracy, leading to diagnosis delays.
“GRIP’s technology will alter this paradigm by providing robust multi-disease diagnostic information at the time and location of need, which is often in the home at the time of symptom onset when rapid access to a clinic’s diagnostic equipment may not be possible.”
GRIP Molecular Technologies is also actively raising investment funding to support the development plans of this diagnostic technology.
Molecular Testing Labs intends to remove barriers to clinical testing where geographic, financial, and stigma barriers make gaps in the delivery of healthcare using its advanced, complex clinical laboratory.
Molecular Testing Labs co-founder and chief innovation officer Adam Blackwell said: “Our collaboration with GRIP is a testament to our shared commitment to empower consumers by providing them ready access to their health information.
“Together, we are committed to developing and offering new technologies that improve health, enhance healthcare experiences, and reduce costs in ways not possible with currently commercialised technologies.”